Results 291 to 300 of about 14,611,928 (419)

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paltusotine is a novel, nonpeptide, selective somatostatin receptor 2 agonist in development for the treatment of acromegaly and carcinoid syndrome. This study investigated the mass balance, routes of excretion, absolute bioavailability and metabolite profile of orally administered paltusotine.
Rosa Luo   +6 more
wiley   +1 more source

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract The development of humanized IgG1 anti‐amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease‐modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United States Food and Drug Administration (US FDA) in July 2023, has ...
Amy Bobbins   +5 more
wiley   +1 more source

When does the placebo effect have an impact on network meta-analysis results? [PDF]

open access: yesBMJ Evid Based Med
Nikolakopoulou A   +5 more
europepmc   +1 more source

Systematic Review and Meta-Analysis of the Placebo Effect and its Correlates in Obsessive Compulsive Disorder. [PDF]

open access: yesCan J Psychiatry, 2023
Mohamadi S   +7 more
europepmc   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet   +6 more
wiley   +1 more source

Notes from the field: The Inflation Reduction Act and Enbrel

open access: yes
Arthritis &Rheumatology, Accepted Article.
Charles L Bennett   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy